[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563051":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":49,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":19,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT+Toripalimab Plus Docetaxel and Cisplatin","EXPERIMENTAL","SBRT for gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin",[13],"Combination Product: SBRT+Toripalimab Plus Docetaxel and Cisplatin",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"COMBINATION_PRODUCT","All participants will receive SBRT (18Gy\u002F3 fractions, QOD ) to gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab (240mg) Plus Docetaxel (75mg\u002Fm2, q3w) and Cisplatin (75mg\u002Fm2, q3w) for 3 cycles. If tumor has complete or partial response at 2 weeks after the last course of neoadjuvant chemotherapy, participants will then receive intensity modulated radiotherapy (54Gy\u002F27 fractions). If tumor is stable or progressive, participants will receive radical resection with or without postoperative intensity modulated radiotherapy when necessary.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Fang-Yun Xie","CONTACT","+8613902205880","xiefy@sysucc.org.cn",{"name":27,"role":23,"phone":19,"phoneExt":19,"email":28},"Dian OuYang","ouyd@sysucc.org.cn",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45,46,47,48],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":27,"role":23,"phone":19,"phoneExt":19,"email":28},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"name":27,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":50,"investigatorFullName":22,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","professor","100563051","phase-2-sbrt-followed-by-chemoimmunotherapy-of-toripalimab-plus-docetaxel-and-cisplatin-for-larynx-preservation-in-patients-with-locally-regionally-advanced-squamous-cell-carcinoma-of-the-larynx-and-hypopharynx-100563051",false,"NCT06611137","SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx","Inclusion Criteria:\n\n* Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th\n* age 18-70\n* PS score 0-1\n* normal functions to tolerate chemotherapy, immunotherapy and radiotherapy\n\nExclusion Criteria:\n\n* Patients with a combination of other malignant tumours\n* Individuals with contraindications to immunotherapy","ALL","18 Years","70 Years",{"count":62,"type":63},35,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx",[69,70],"Laryngeal Cancer","Hypopharynx Cancer",[72,73,74,75,76],"SBRT","immunotherapy","larynx preservation","laryngeal cancer","hypopharynx cancer","2024-09-25",{"date":79,"type":80},"2024-09-26","ACTUAL",{"date":82,"type":80},"2024-09-11",{"date":84,"type":63},"2027-09-11",{"name":5,"class":6},1]